FDA approves Alcon’s AcrySof IQ PanOptix trifocal IOL
Summary
Alcon (NYSE:ALC) said today that it won FDA approval for its AcrySof IQ PanOptix trifocal intraocular lens and is preparing an initial commercial launch for the device. FDA approval followed a U.S. pivotal study that revealed uninterrupted vision and high patient satisfaction (99%) from the PanOptix lenses, according to the company. It also intends to launch a PanOptix website and incorporate activities for eye care professionals at the annual meeting of the American Academy of Ophthalmology in October. “We are proud to bring this new class of IOLs to the largest eye care market in the world,” Alcon CEO David Endicott said in prepared remarks. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.” “The U.S. ophthalmology community has been eagerly awaiting FDA approval of PanOptix,” added clinical investigator Dr. Kerry Solomon of Carolina Eyecare Physicians.
Classifications
AskAI Classifications
LabelsLinked Companies
